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mutant. Most prominently, the level of phosphorylation phorylation, whose levels are significantly reduced in
of the pol II C-terminal domain (CTD) is significantly de- strains lacking Dsg1/Mdm30 and whose central role in
creased both at Ser2 and Ser5, the positions in the CTD coordinating RNA synthesis and maturation is well
repeat usually phosphorylated in elongating pol II (Sims established. An investigation of how the ubiquitylation
et al., 2004). As CTD phosphorylation is required for the and elimination of a most well-studied activator, Gal4,
recruitment of several factors required for mRNA matu- leads to proper CTD phosphorylation and progression
ration, this defect is likely the cause of the other de- of the transcription cycle will likely provide general in-
fects detected, including the lack of association of sights into the control of gene expression. The work of
GAL1 mRNA with polysomes. Taken together, these re- Muratani et al. (2005), therefore, both adds significantly
sults suggest that Gal4 ubiquitylation and turnover play to our knowledge in the area of transcriptional regula-
a key role in Gal4 activation at a level that affects mRNA tion and sets the stage for what will likely include addi-
maturation. The authors suggest a model in which Gal4 tional surprising results.
destruction promotes disassembly of the initiation
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the only target of Dsg1/Mdm30 that is relevant to GAL Harvard Medical School
gene activation. While Muratani et al. (2005) clearly de- Boston, Massachusetts 02115
monstrate effects of Dsg1/Mdm30 on Gal4 ubiquityla-
tion and stability, it remains possible that Dsg1/Mdm30
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is that Dsg1/Mdm30 may recruit components of the
proteasome, which have been argued to play nonpro-
teolytic roles in transcription elongation (Lipford and
Deshaies, 2003; Muratani and Tansey, 2003). If Gal4
turnover is indeed essential for activation, this would
suggest that activated Gal4 must be regenerated with
each new round of transcription. For the GAL genes,
then, each round of transcription could be viewed as a
“pioneer” round requiring reassembly of an initiation
complex.
Given the importance of Gal4 ubiquitylation, the reg-
ulation of Dsg1/Mdm30 itself becomes an important is-
sue. Is association of Dsg1/Mdm30 with the GAL1-
GAL10 UAS regulated by galactose or dependent upon
known coactivator complexes, such as SAGA? Is Dsg1/
Mdm30 itself part of a known coactivator complex?
Does it activate Gal4 in conditions where galactose is
not needed for GAL gene induction, such as in a grr1D
mutant grown in raffinose?
Finally, and most importantly, the mechanism by
which activator function is tied to a productive transi-
tion from initiation to elongation remains to be eluci-
dated. Future studies will certainly focus on CTD phos-DOI 10.1016/j.cell.2005.03.004
San1p, Checking up
on Nuclear Proteins
Cellular quality control mechanisms perform vital
tasks by ensuring that the proteome reflects precisely
the information encoded by the genome. In this issue
of Cell, Gardner et al. (2005) report the discovery of a
novel protein quality control system that resides in
the nucleus. Central to this system is the E3 ligase
San1p, which monitors nuclear proteins and targets
aberrant species for destruction.
The life of a protein can be terminated for many
reasons. Numerous cellular processes require the timed
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735breakdown of regulatory factors. Proteins that are not
subjected to regulated degradation deteriorate eventu-
ally and become detrimental to cellular function. To
protect the cell from damage caused by malfunctioning
polypeptides, protein quality control (PQC) systems
have evolved that target defective proteins and attempt
to restore their native conformation. Only proteins be-
yond rescue are destroyed. These proteins, however,
are not the only source of aberrant proteins. Experi-
mental data suggest that approximately 30% of all
newly synthesized proteins fail to acquire their native
structure (Schubert et al., 2000). To ensure that these
waste products of protein synthesis are degraded
promptly, PQC systems are located in compartments
where protein maturation takes place: the cytosol, the
endoplasmic reticulum (ER), and mitochondria (Arnold
and Langer, 2002; Cyr et al., 2002; Hirsch et al., 2004).
Most likely, these PQC systems also take charge of ab-
normal proteins that have been damaged posttransla-
tionally by aging or environmental stress. The impor-
tance of PQC systems for the maintenance of cellular
homeostasis becomes immediately evident from the
various pathologies such as Alzheimer’s, Huntington’s,
and Parkinson’s diseases, which are all linked to de-
fects in protein quality control (Selkoe, 2003).
The hallmarks of a PQC system are proof-reading,
refolding, and degradation. Central to protein quality
control is the proof-reading step where proteins are
either returned for refolding or sentenced for destruc-
tion. One of the factors that judges over the fate of mal-
folded proteins is the cytosolic U box ubiquitin-ligase
CHIP (Cyr et al., 2002). Equipped with a tetratricopep-
tide repeat domain, CHIP interacts with chaperones
such as hsp70-hsp90 and screens their cargo. Folding-
incompetent proteins are ubiquitinated by CHIP and
subsequently degraded. The stoichiometry between
chaperones and CHIP determines the balance between
folding and degradation: elevated levels of CHIP in-
crease the stringency of the proof-reading step by en-
hancing the rate at which degradation occurs.
While our understanding of the mechanisms that
govern quality control in the cytosol and the ER ad-
vances, evidence for a nuclear PQC counterpart has
remained elusive. An astounding number of pathways
for the regulated degradation of nuclear substrates
have been characterized, but a PQC system that elimi-
nates aberrant proteins from this organelle has not
been described so far. Still, such a system must exist
since many proteins are restricted to the nucleus by a
nuclear localization sequence and thus unavailable for
cytosolic PQC systems. This raises the intriguing ques-
tion as to how dysfunctional proteins are disposed from
the nucleus.
In this issue of Cell, Gardner et al. (Gardner et al.,
2005) come forward with the first answers to this ques-
tion using a sophisticated approach: certain mutations
do not impair the biological activity of a protein but
rather attract the attention of a PQC system that inad-
vertently eliminates the affected protein. The pheno-
type of such a mutation is caused only by the reduced
steady-state levels of the mutated protein. Defects in
the PQC system that degrades the mutant protein can
therefore restore protein levels and rescue the pheno-
type. Based on this concept, Gardener et al. searchedin silico for a common extragenic suppressor that res-
cues conditional alleles of nuclear proteins. Such a
screen should yield potential components of a nuclear
PQC system.
Gardener et al. found two genetic analyses which
had previously shown that mutations in the yeast pro-
tein San1p rescue the phenotype of temperature-sensi-
tive alleles in two unrelated nuclear proteins. These re-
sults made San1p an excellent candidate for a factor
that partakes in the degradation of malfolded nuclear
proteins. To verify this hypothesis, the authors exam-
ined the effect of a SAN1 deletion on the stability of
four distinct nuclear proteins and their mutated coun-
terparts. Indeed, San1p targeted exclusively the mal-
folded forms of the studied substrates for degradation
while leaving the respective native proteins unscathed.
It is important to note that lack of SAN1 does not alter
the in vivo function of the native substrates, an obser-
vation that lends further support to the conclusion that
San1p is part of a quality control and not a regulatory
system. But what is the molecular function of San1p in
this process? San1p contains a RING finger domain,
which is characteristic for a class of ubiquitin ligases
that targets proteins for degradation by the protea-
some. Using an in vitro assay, the authors confirm that
San1p possesses ubiquitin-ligase activity that requires
the RING finger domain. In vivo, San1p function de-
pends on its RING finger and nuclear localization. Mis-
localization of San1p to the cytosol abrogates the turn-
over of malfolded nuclear proteins.
Since San1p and CHIP both mediate ubiquitination
and thus destruction, it is likely that San1p is a nuclear
proof-reading factor that links protein remodeling to the
ubiquitin-proteasome pathway. Many questions can
now be asked to further our understanding of this excit-
ing new process: Which factors operate upstream of
San1p? How is the specificity of this PQC system en-
sured? The ligase recognizes very different substrates,
suggesting that San1p may utilize adaptor proteins to
recognize its targets. Could these adaptor proteins be
part of a nuclear chaperone system that remodels mal-
folded proteins? Alternatively, the San1p-dependant
PQC system may be much more rigorous than other
quality control systems and degrade aberrant proteins
without an attempt for repair.
The physiological relevance of San1p is underscored
by the fact that deletion of SAN1 triggers a cellular
stress response. Still, lack of San1p does not render
yeast cells more susceptible to stress, indicating that
back up mechanisms may exist that compensate for
loss of San1p. Most certainly, higher eukaryotes pos-
sess similar nuclear PQC systems and their importance
remains to be established. In contrast to yeast cells,
which are probably better equipped to handle cellular
stress, defects in nuclear PQC pathways of long-lived
cells like neurons may be much more serious. It is quite
possible that a number of pathologies will be linked to
defects in nuclear protein quality control in the near future.
Thomas Sommer and Christian Hirsch
Max-Delbrück Center for Molecular Medicine
Robert-Rossle Str. 10
D-13092 Berlin
Germany
Cell
736Selected Reading
Arnold, I., and Langer, T. (2002). Biochim. Biophys. Acta 1592, 89–
96.
Cyr, D.M., Hohfeld, J., and Patterson, C. (2002). Biochem. Sci. 27,
368–375.
Gardner, R.G., Nelson, Z.W., and Gottschling, D.E. (2005). Cell 120,
this issue, 803–815.
Hirsch, C., Jarosch, E., Sommer, T., and Wolf, D.H. (2004). Biochim.
Biophys. Acta 1695, 215–223.
Schubert, U., Anton, L.C., Gibbs, J., Norbury, C.C., Yewdell, J.W.,
and Bennink, J.R. (2000). Nature 404, 770–774.
Selkoe, D.J. (2003). Nature 426, 900–904.
DOI 10.1016/j.cell.2005.03.003
